Skip to main content Help with accessibility Skip to main navigation

Fidaxomicin

Indication

Treatment of Clostridium difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adults
Amber level 0

Brand:

Dificlir

Nice TA:

Commissioning responsibility:

CCG

PbR excluded:

No

BNF chapter:
Infection

Background

Fidaxomicin should be initiated by a microbiologist or under microbiologist recommendation.
Fidaxomicin (Dificlir®) to be considered as an option for use following a first or second relapse. i.e. as second or third line therapy.
Fidaxomicin to also be considered for patients with severe CDI who are considered to be at high risk for recurrence as per the Public Health England Guidance. e.g. elderly patients with multiple comorbidities who are receiving concomitant antibiotics and those not responding to oral vancomycin.

Recommendation

LSCMMG Recommendation:

Amber level 0

Reason for decision:

Suitable for GP prescribing following recommendation/initiation by specialist

Decisions of Lancashire local decision making groups

Amber 0
Amber 0
Amber 0
Amber 0
Amber 0
Amber 0
Pending
Pending
What do the colours mean?

Last Updated: 01 - Sep - 2019